Abstract:Tuberculosis (TB), caused by the airborne bacterial pathogen Mycobacterium tuberculosis, remains a major source of morbidity and mortality worldwide. So far, the study of host-pathogen interactions in TB has mostly focused on the physiology and virulence of the pathogen, as well as, on the various innate and adaptive immune compartments of the host. Microbial organisms endogenous to our body, the so-called microbiota, interact not only with invading pathogens, but also with our immune system. Yet, the impact of the microbiota on host defense against M. tuberculosis remains poorly understood. In order to address this question, we adapted a robust and reproducible mouse model of microbial dysbiosis based on a combination of wide-spectrum antibiotics. We found that microbiota dysbiosis resulted in an increased early colonization of the lungs by M. tuberculosis during the first week of infection, correlating with an altered diversity of the gut microbiota during this time period. At the cellular level, no significant difference in the recruitment of conventional myeloid cells, including macrophages, dendritic cells and neutrophils, to the lungs could be detected during the first week of infection between microbiota-competent and -deficient mice. At the molecular level, microbiota depletion did not impact the global production of pro-inflammatory cytokines, such as interferon (IFN)γ, tumor necrosis factor (TNF)α and interleukin (IL)-1β in the lungs. Strikingly, a reduced number of mucosal-associated invariant T (MAIT) cells, a population of innate-like lymphocytes whose development is known to depend on the host microbiota, was observed in the lungs of the antibiotics-treated animals after 1week of infection. These cells produced less IL-17A in antibiotics-treated mice. Notably, dysbiosis correction through the inoculation of a complex microbiota in antibiotics-treated animals reversed these phenotypes and improved the ability of MAIT cells to proliferate. Altogether, our results demonstrate that the host microbiota contributes to early protection of lung colonization by M. tuberculosis, possibly through sustaining the function(s) of MAIT cells. Our study calls for a better understanding of the impact of the microbiota on host-pathogen interactions in TB. Ultimately, this study may help to develop novel therapeutic approaches based on the use of beneficial microbes, or components thereof, to boost anti-mycobacterial immunity.

Intestinal microbiome dysbiosis increases Mycobacteria pulmonary colonization in mice by regulating the Nos2- associated pathways

Intestinal microbiome dysbiosis increases pulmonary colonization in mice by regulating the associated pathways

The gut microbiota mediates protective immunity against tuberculosis via modulation of lncRNA

Gut microbiota dysbiosis-related susceptibility to nontuberculous mycobacterial lung disease

Gut Dysbacteriosis Attenuates Resistance to Mycobacterium Bovis Infection by Decreasing Cyclooxygenase 2 to Inhibit Endoplasmic Reticulum Stress

The Host Microbiota Contributes to Early Protection Against Lung Colonization by Mycobacterium tuberculosis

Mycobacterium tuberculosis, antimicrobials, immunity, and lung-gut microbiota crosstalk: current updates and emerging advances

Gut Microbiota Regulates Mincle Mediated Activation of Lung Dendritic Cells to Protect Against Mycobacterium tuberculosis

Interaction Between Gut Microbiota Dysbiosis and Lung Infection As Gut-Lung Axis Caused by Streptococcus Suis in Mouse Model

Macrophage-mediated Inflammatory Response Decreases Mycobacterial Survival in Mouse MSCs by Augmenting NO Production

Dysbacteriosis of Gut Microbiota Induces the Down-Regulation of TollLike Receptor 7 and RIG-I-like Receptors in Virus-Infected Mice

Obesity-Induced Dysbiosis Exacerbates IFN-γ Production and Pulmonary Inflammation in the Mycobacterium tuberculosis Infection

Mycobacterium tuberculosis Rv1987 protein attenuates inflammatory response and consequently alters microbiota in mouse lung

Gut microbiota: a crucial player in the combat against tuberculosis

MiR‐342 Controls Mycobacterium Tuberculosis Susceptibility by Modulating Inflammation and Cell Death

Gut microbiota associated with pulmonary tuberculosis and dysbiosis caused by anti-tuberculosis drugs.

Microbiota and Tuberculosis: A Potential Role of Probiotics, and Postbiotics

Mitigation of Dextran-Sodium-Sulfate-Induced Colitis in Mice through Oral Administration of Microbiome-Derived Inosine and Its Underlying Mechanisms

Non-tuberculous mycobacteria enhance the tryptophan-kynurenine pathway to induce immunosuppression and facilitate pulmonary colonization

Anaerobe-enriched gut microbiota predicts pro-inflammatory responses in pulmonary tuberculosis

Enteric infection coupled with chronic Notch pathway inhibition alters colonic mucus composition leading to dysbiosis, barrier disruption and colitis